Most Clicked StoriesMore >


Commentary: FDA's proposed guidance on off-label communications may spur discussion

DIA Global SmartBrief | Apr 30, 2015

The FDA's recent proposed guidance on off-label communications may finally prompt a serious discussion of the differences between off-label communications and off-label marketing, writes Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest. "The new FDA draft guidance opens the door for companies to share truthful, scientifically accurate and data-driven information with health care professionals to inform treatment decisions," he contends. Medical Marketing & Media (04/29)


Takeda to settle Actos cancer-risk lawsuits for about $2.4B

DIA Global SmartBrief | Apr 30, 2015

Asian generic market expected to surge as drugs go off-patent

DIA Global SmartBrief | Apr 28, 2015

Antitrust experts worry a Teva-Mylan merger would exacerbate drug shortages

DIA Global SmartBrief | Apr 28, 2015

Sleep-wake disorder, skin cancer, 9 other drugs get nod for European approval

DIA Global SmartBrief | Apr 28, 2015

Drug developers target celiac disease, gluten sensitivity

DIA Global SmartBrief | Apr 30, 2015

Electroceuticals disrupt neuroscience

DIA Global SmartBrief | Apr 30, 2015

Trial in Colombia aims to prove drug can stave off early-onset Alzheimer's

DIA Global SmartBrief | Apr 28, 2015

More pharma companies are using social media

DIA Global SmartBrief | Apr 28, 2015

Australian regulators approve new code of conduct for doctors' pharma perks

DIA Global SmartBrief | Apr 30, 2015


Find DIA Global SmartBrief Issues by Date:



DIA News More >


DIA's upcoming educational programs

DIA Global SmartBrief | Apr 30, 2015

DIA China 7th Annual Meeting

DIA Global SmartBrief | Apr 28, 2015

DIA works to globally advance the science of safety

DIA Global SmartBrief | Apr 23, 2015

DIA 2015 51st Annual Meeting

DIA Global SmartBrief | Apr 21, 2015

Risk-based monitoring sessions at DIA 2015

DIA Global SmartBrief | Apr 14, 2015




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more